Platelet-derived miR-92a downregulates cysteine protease inhibitor cystatin C in type II diabetic lower limb ischemia

Experimental and Therapeutic Medicine

Volumn 9, Issue 6, 2015, Pages 2257-2262

  Zhang, Yunfeng ^a,b   Guan, Qiang ^b   Jin, Xing ^a  

^a SHANDONG UNIVERSITY   (China)

^b SHAANXI PROVINCIAL PEOPLE S HOSPITAL   (China)

Author keywords

Cystatin C; MiR 92a; Platelet; Type II diabetic lower limb ischemia

Indexed keywords

CHOLESTEROL; CYSTATIN C; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MICRORNA; MICRORNA 92A; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; ANKLE BRACHIAL INDEX; ARTICLE; BIOINFORMATICS; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENETIC TRANSFECTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; INSULIN RESISTANCE; LEG ISCHEMIA; MAJOR CLINICAL STUDY; MALE; MRNA EXPRESSION ASSAY; NEPHELOMETRY; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 84928243659     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2015.2400     Document Type: Article

References (24)

1. Ouriel K: Peripheral arterial disease. Lancet 358: 1257-1264, 2001.
2. Beckman JA, Creager MA and Libby P: Diabetes and atherosclerosis: Epidemiology, pathophysiology and management. JAMA 287: 2570-2581, 2002.
3. Ridker PM, Cushman M, Stampfer MJ, Tracy RP and Hennekens CH: Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 97: 425-428, 1998.
4. Arain FA and Cooper Jr LT: Peripheral arterial disease: Diagnosis and management. Mayo Clin Proc 83: 944-949, 2008.
5. Abrahamson M, Olafsson I, Palsdottir A, Ulvsbäck M, Lundwall A, Jensson O and Grubb A: Structure and expression of the human cystatin C gene. Biochem J 268: 287-294, 1990.
6. Koenig W, Twardella D, Brenner H and Rothenbacher D: Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: More than simply a marker of glomerular filtration rate. Clin Chem 5l: 321-327, 2005.
7. Watanabe S, Okura T, Liu J, Miyoshi K, et al: Serum cystatin C level is a marker of end-organ damage in patients with essential hypertension. Hypertens Res 26: 895-899, 2003.
8. Arpegård J, Ostergren J, de Faire U, Hansson LO and Svensson P: Cystatin C - A marker of peripheral atherosclerotic disease? Atherosclerosis 199: 397-401, 2008.
9. de Groot M, Anderson R, Freedland KE, Clouse RE and Lustman PJ: Association of depression and diabetes complications: A meta-analysis. Psychosom Med 63: 619-630, 2001.
10. Liu F, Shen J, Zhao J, et al: Cystatin C: A strong marker for lower limb ischemia in Chinese type 2 diabetic patients? PloS One 8: e66907, 2013.
11. Berezikov E, Cuppen E and Plasterk RH: Approaches to microRNA discovery. Nat Genet 38 (Suppl): S2-S7, 2006.
12. Stuwe E, Tóth KF and Aravin AA: Small but sturdy: Small RNAs in cellular memory and epigenetics. Genes Dev 28: 423-431, 2014.
13. Liu D, Tao T, Xu B, et al: MiR-361-5p acts as a tumor suppressor in prostate cancer by targeting signal transducer and activator of transcription-6 (STAT6). Biochem Biophys Res Commun 445: 151-156, 2014.
14. Loyer X, Potteaux S, Vion AC, et al: Inhibition of microRNA-92a prevents endothelial dysfunction and atherosclerosis in mice. Circ Res 114: 434-443, 2014.
15. Sun X, Belkin N and Feinberg MW: Endothelial microRNAs and atherosclerosis. Curr Atheroscler Rep 15: 372, 2013.
16. Vickers KC, Rye KA and Tabet F: MicroRNAs in the onset and development of cardiovascular disease. Clin Sci (Lond) 126: 183-194, 2014.
17. Creemers EE, Tijsen AJ and Pinto YM: Circulating microRNAs: Novel biomarkers and extracellular communicators in cardiovascular disease? Circ Res 110: 483-495, 2012.
18. Huo Y, Schober A, Forlow SB, et al: Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med 9: 61-67, 2003.
19. Wilcox JN, Smith KM, Williams LT, Schwartz SM and Gordon D: Platelet-derived growth factor mRNA detection in human atherosclerotic plaques by in situ hybridization. J Clin Invest 82: 1134-1143, 1988.
20. Huo Y and Ley KF: Role of platelets in the development of atherosclerosis. Trends Cardiovasc Med 14: 18-22, 2004.
21. Nomura S, Suzuki M, Katsura K, et al: Platelet-derived microparticles may influence the development of atherosclerosis in diabetes mellitus. Atherosclerosis 116: 235-240, 1995.
22. Shi GP, Sukhova GK, Grubb A, et al: Cystatin C deficiency in human atherosclerosis and aortic aneurysms. J Clin Invest 104: 1191-1197, 1999.
23. Taglieri N, Koenig W and Kaski JC: Cystatin C and cardiovascular risk. Clin Chem 55: 1932-1943, 2009.
24. Watanabe S, Okura T, Liu J, Miyoshi K, Fukuoka T, Hiwada K and Higaki J: Serum cystatin C level is a marker of end-organ damage in patients with essential hypertension. Hypertens Res 26: 895-899, 2003.